Clinical trial · Interventional
Pre-Exercise for Allogeneic Stem Cell Transplant Patients
Pre-Exercise for Allogeneic Stem Cell Transplant Patients: a Pilot Study
NCT03080792CI-TRIAL-00052106PRESENT-PterminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Recruitment difficult
Summary
Brief summary (as posted)
The PRESENT-P study is a one-arm exercise intervention study for hematological cancer patients prior allogeneic stem cell transplantation (allo-HCT). This pilot study will investigate in a prehabilitation approach the safety and feasibility of high-intensity exercise program directly prior transplantation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer, Hematological | Malignant Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Experimental: moderate to high-intensity exercise | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Exercise
- description
- Exercise Intervention, moderate to high-intensity endurance and resistance exercise
- interventionNames
- Behavioral: Experimental: moderate to high-intensity exercise
Primary outcomes (2)
- measure
- Feasibility of supervised high-intensity aerobic exercise training and high-intensity resistance training prior allo-HCT in hematological cancer patients. Measured as adherence to the training protocol
- timeFrame
- 4-12 weeks
- description
- Adherence is defined as \>50% of prescribed exercise sessions completed.
- measure
- Safety of supervised high-intensity exercise aerobic exercise training and high-intensity resistance training prior allo-HCT in hematological cancer
- timeFrame
- 4-12 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Hematological cancer, e.g. AML, CLL, MM * Scheduled for allo-HCT at the University Clinic Heidelberg or other cooperation sites within the next 4-12 weeks * Patients ≥ 18 years of age * Sufficient German language skills * Willing/ able to train at the provided exercise facilities twice per week and to take part in the scheduled testing * Signed informed consent Exclusion Criteria: * Heart insufficiency \> NYHA III or uncertain arrhythmia * Uncontrolled hypertension * Severe renal dysfunction (GFR \< 30%, Creatinine\> 3mg/dl) * Reduced standing or walking ability * Insufficient hematological capacity (either hemoglobin value below 8 g/dl or thrombocytes below 30.000/µL) * Any other comorbidities that preclude participation in the exercise programs * Engaging in systematic intense exercise training (at least 1h twice per week)
References
Publications (0)
Data not yet available
No reference posted for this study.